The CAR-T Capital

In one corner of advanced medicine, China does not trail the United States; it leads it outright. As of mid-2025 China had about 1,006 registered clinical trials of CAR-T cell therapy, the technique that re-engineers a patient’s own immune cells to attack cancer, against 549 in the United States.^[1] Between them the two countries account for more than 80% of all such trials worldwide, and China is the larger share.

The pace is not slowing: more than 250 new CAR-T trials were registered in China in 2024 alone.^[1] What enables the volume is structural. A hospital-based pathway lets Chinese institutions launch investigator-initiated trials faster and more cheaply than the industry-sponsored model that dominates in the West, a regulatory design that turns China into the world’s busiest cell-therapy laboratory.^[4]

A thousand trials is a remarkable number. It is a measure of activity, not yet of approved, commercialised cures.

From trial to product

The commercial proof exists too. Carvykti, a therapy discovered by China’s Legend Biotech and partnered with Johnson & Johnson, recorded about $963 million in net trade sales in 2024, won an expanded US approval for earlier use in 2024, and became the first cell therapy shown to extend overall survival against the standard of care.^[2][3] A China-originated science became a global product.

Here is the asterisk. Trial count is a measure of activity, not of commercialised leadership: the United States still leads in approved, scaled cell-therapy products, and much of China’s volume is early-phase and academic. And Legend, though Chinese-founded, is Nasdaq-listed and operates globally, “China-originated” is more precise than “a Chinese product.” The lead is real; it is a lead in research intensity.

What this changes

Cell therapy is the clearest example of China converting structural advantages, scale, speed, a permissive trial pathway, into a genuine research frontier lead, and it is a template for how the country competes in cutting-edge biology. The investable reading is to separate the two scoreboards: research intensity, where China is first and the pipeline of shots-on-goal is unmatched, and commercial translation, where the West still converts more trials into approved, reimbursed products. The opportunity sits in the firms bridging the two, China-originated assets, like Carvykti, that reach global markets, and the risk sits in mistaking a thousand early trials for a thousand cures.